On August 05, 2022, in order to better implement the “Healthy China 2030” Plan and following the deployment of the State Council to promote the construction of a tiered diagnosis and treatment system, under the guidance of relevant authorities of the National Health Commission, the “Spark Plan-Standardized Diagnosis and Treatment of Drug-induced Liver Diseases in 100 Counties” project, jointly initiated by the Technical Committee for the Prevention and Treatment of DILI of the China Medical Biotechnology Association, the Drug-induced Liver Disease Group of the Hepatology Branch of the Chinese Medical Association, and the China Medical Tribune, and supported by Beijing Union Pharmaceutical Factory LTD, was launched in Beijing.

This project belongs to the “Community Standardized Diagnosis and Treatment Training Project” of the National Health Commission, aiming to focus on standardized diagnosis and treatment of diseases, further explore and summarize the clinical diagnosis and treatment experience of drug-induced liver diseases in China, better promote and popularize disease knowledge to medical professionals in community clinics, and promote clinicians’ standardized diagnosis and treatment exchanges. Drug-induced liver injury (DILI) refers to liver injuries induced by various prescription or over-the-counter chemical drugs, biological preparations, traditional Chinese medicines, natural medicines, health care products, dietary supplements and their metabolites, and even excipients. DILI is one of the most common and serious adverse drug reactions, and in severe cases, it can lead to acute liver failure or even death.

Excerpted from: People Daily Health Client